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Abstract
Introduction: Cardiovascular complications are a major cause of morbidity and mortality in patients with uncontrolled 
acromegaly. However, there are no published reports of an increased risk of venous thromboembolism (VTE) in such 
patients. We report three patients with uncontrolled acromegaly who presented with VTE.
Clinical Cases: A 52-year-old male with uncontrolled acromegaly despite transsphenoidal (TSP) surgery and medical 
therapy presented in 2012 with acute chest pain and shortness of breath that was later confirmed as secondary to 
pulmonary embolism. A 44-year-old male immigrant, previously treated for acromegaly with radiation therapy alone, 
in 1992, in his native country, was referred to our centre in 2006 for acromegaly which remained uncontrolled despite 
medical therapy until 2009 when he achieved remission through TSP surgery. He had several episodes of VTE between 
2008 and 2010. A 69-year-old male with uncontrolled acromegaly for 28 years despite two surgical resections and 
radiation therapy in 1986 and 1992, as well as continuous medical therapy, presented with VTE of the right axillary 
vein and bilateral pulmonary emboli in 2011. A thrombophilia screen in case 1 showed mild protein S deficiency, case 2 
was homozygous for factor V Leiden (FVL) mutation and case 3 was heterozygous for FVL. Extensive investigations 
revealed no evidence of malignancy and echocardiography showed preserved ejection fraction in all three patients.
Conclusion: Patients with uncontrolled acromegaly may be at increased risk of VTE. However, larger studies are 
required to further assess this association and determine the underlying cause.
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Introduction
Uncontrolled acromegaly is associated with an increased 
risk of cardiovascular (CV) abnormalities such as 
hypertension, left ventricular hypertrophy (LVH), 
endothelial dysfunction and cardiomyopathy.[1] In fact, CV 
complications constitute the leading cause of morbidity 
and mortality in patients with acromegaly.[2] Recent 
reports have suggested that changes in the coagulation and 
fibrinolytic system may also play a role in the pathogenesis 
of CV disease in acromegaly.[3-5] To date, there are 
no published reports of an increased risk of venous 
thromboembolism (VTE) in acromegaly. We report three 
cases of patients with uncontrolled acromegaly who 
presented with extensive VTE.
Case Reports
Case 1
A 52-year-old Caucasian male presented with typical 
phenotypic features of acromegaly in December 2009. 
Baseline serum IGF-1 and growth hormone (GH) levels 
were 1220 mcg/l (n 87–238) and 54.1 mcg/l (n <1 mcg/l), 
respectively; nadir GH after an oral glucose tolerance test 
was 29.3 mcg/l. Magnetic resonance imaging (MRI) of the 
sella revealed a 1.4 cm pituitary adenoma extending into 
the right cavernous sinus. He underwent transsphenoidal 
(TSP) tumour resection in June 2011, which led to a 
significant reduction in serum IGF-1, albeit without 
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normalisation, at 15–20 % above the upper limit of normal 
(ULN). Follow-up MRI revealed a small residual tumour 
and the patient was offered repeat surgery or radiation 
therapy, which he declined. Due to the absence of medical 
coverage for somatostatin analogue therapy, cabergoline or 
pegvisomant, pharmacologic therapy with bromocriptine 
(10 mg daily) was initiated. He was unable to tolerate 
a larger dose due to nausea and dizziness. There was a 
slight reduction in his serum IGF-1, but it has remained 
uncontrolled, with serum IGF-1 consistently between 10 
and 13% above ULN. To date, he declines further medical 
intervention. In September 2012, he presented with acute 
chest pain and shortness of breath and was subsequently 
diagnosed with a right upper lobe pulmonary embolism on 
computed tomography (CT) pulmonary angiography. No 
other risk factors for thromboembolism such as immobility, 
recent travel, malignancy or family history of VTE were 
identified. Anticoagulation with low molecular weight 
heparin was initiated until adequate warfarin therapy 
was established; he currently remains on a daily dose of 
10 mg. A colonoscopy was performed in October 2012 
which revealed three benign hyperplastic polyps and an 
echocardiogram showed mild diastolic left ventricular 
dysfunction but preserved systolic function. Thrombophilia 
screen [Table 1] revealed the following results: Fibrinogen 
3.81 g/L (n = 2.15–4.79), negative D-Dimer (negative 
< 200 ng/mL), protein C 1.03 U/mL (n = 0.74–1.64), 
protein S 0.66 U/mL (n = 0.7–1.47) and negative Factor 
V Leiden (FVL) and prothrombin gene mutations.
Case 2
A 44-year-old South Asian male who had recently 
immigrated to Canada was referred to our clinic in 2006. 
He had been diagnosed with acromegaly in his native 
country in 1990 where, in 1992, he was treated with 
radiation therapy only. Biochemical evaluation revealed an 
elevated IGF-1 of 352 mcg/l (n = 109–284) and multiple 
pituitary insufficiencies for which replacement therapy, in 
the form of hydrocortisone, L-thyroxine and testosterone, 
were initiated. Pituitary MRI showed a 7 mm left-sided 
pituitary tumour. Medical therapy with Sandostatin 
LAR 30 mg was initiated immediately and pegvisomant 
(15 mg daily) was added 6 months later for persistent 
disease (IGF-1 = 338 mcg/l). This resulted in transient 
normalisation of IGF-1, but serum IGF-1 started rising 
again in early 2009 with evidence of persistent 7 mm 
adenomatous tissue on MRI of the sella. He underwent 
TSP tumour resection in November 2009, which resulted 
in normalisation of serum IGF-1. He has remained 
in remission since then. Between 2008 and 2010, the 
patient developed two episodes of right thigh superficial 
thrombophlebitis (August 2008 and January 2010), two 
episodes of left saphenous vein thrombosis (November 
2008), left popliteal vein thrombosis (February 2010) and 
pulmonary embolism diagnosed by a ventilation-perfusion 
scan (February 2010). Risk factors such as family history 
of VTE, immobility, recent travel or history of malignancy 
were not identified and he was initiated on long-term 
Table 1: Thrombophilia screen*
Tests Case 1 Case 2 Case 3 
Fibrinogen (2.15–4.79 g/L) 3.81 4.75 3.83 
Antithrombin III (0.80–1.40 U/ml) NA a 0.94 0.86 
D‑Dimer (negative<200 ng/mL) Negative Negative NA 
Anti cardiolipin IgG (negative: <10 U/ml) 4.6 5.3 1.60 
Lupus anticoagulant ratio (0.8–1.2) NA 1.4b 1.0 
Homocysteine (7.1–17.3 μmol/L) 14 NA 16.5 
Protein C (0.74–1.64 U/mL) 1.03 NA 1.60 
Protein S (0.7–1.47 U/mL) 0.66 (INR c NA) NA 1.98 
Factor V Leiden mutation Negative Homozygous Heterozygous 
Prothrombin G20210A mutation Negative Negative Negative 
*None of the workup was done during the acute thrombosis episode. For patients on warfarin, Protein C and Protein S were measured 7 days 
after discontinuing warfarin; anticoagulation therapy was switched to SC LMW heparin. Serum antithrombin III and fibrinogen levels were 
checked simultaneously. aNot available. bRatio: > 2.0 LA is strongly present. 1.6–2.0 LA is moderately present. 1.3–1.5 LA is weakly present. 
cInternational normalised ratio
JOURNAL OF CANCER & ALLIED SPECIALTIES 3
ORIGINAL ARTICLE J Cancer Allied Spec 2015;1(1):6
anticoagulation therapy with warfarin. A colonoscopy was 
performed in June 2010 which showed no abnormality and 
an echocardiogram from October 2012 revealed mild LVH 
but was otherwise unremarkable. Thrombophilia workup 
showed the following: Fibrinogen 4.75 g/L, antithrombin 
III 0.94 U/mL (n = 0.80–1.40), anticardiolipin IgG 
5.3 U/mL (negative = <10 U/ml), lupus anticoagulant 
ratio 1.4 (n = 0.8–1.2) and homozygous FVL mutation.
Case 3
A 69-year-old Caucasian male was originally diagnosed 
with acromegaly in 1985 while living in another province. 
He had undergone TSP surgery in 1986, followed 
immediately by fractionated radiotherapy (5000 cGY). 
Serum GH and IGF-1 levels remained elevated despite 
high-dose bromocriptine and Sandostatin (100 mcg 
TID) until he underwent further surgery followed by 
additional fractionated radiotherapy (2500 cGY) in 
1993. He underwent drainage of an abscess in his left 
thigh in 2000 when he developed an episode of left 
calf deep vein thrombosis (DVT) that was treated with 
short-term anticoagulation therapy. He moved to Nova 
Scotia in 2005 and was referred to our centre. Initial 
assessment revealed multiple pituitary insufficiencies 
requiring hydrocortisone, L-thyroxine and testosterone 
replacement therapy. Pituitary MRI showed an empty 
sella, with no evidence of pituitary tumour. However, due 
to a persistently elevated serum IGF-1, he was maintained 
on octreotide LAR 30 mg every 4 weeks initially and 
subsequently switched to lanreotide 120 mg every 4 weeks 
in November 2008. His serum IGF-1 remained elevated. 
In 2010, he developed atrial fibrillation and was initiated 
on dabigatran. Pegvisomant 15 mg daily was added 
in February 2011, which resulted in normalisation of 
IGF-1 (194 mcg/l; n 69–200). He presented to his local 
hospital in July 2011 with right upper limb swelling, pain 
and redness as well as intermittent fever, pleuritic chest 
pain and shortness of breath. Duplex ultrasound showed 
occlusive venous thrombus in his right axillary vein and 
CT pulmonary angiogram revealed bilateral pulmonary 
emboli. Anticoagulation was initiated with IV heparin 
followed by warfarin. Both Sandostatin and pegvisomant 
were discontinued on this admission. Subsequently, 
pegvisomant was restarted in September 2011 and titrated 
to 20 mg daily in December 2011, leading to normalisation 
of serum IGF-1 (he was unwilling to take Sandostatin 
therapy). In October 2012, warfarin was discontinued and 
dabigatran 150 mg BID was restarted due to difficulty 
achieving a consistently therapeutic INR on warfarin. He 
underwent left total knee replacement in December 2012 
and 8 weeks later, while still on dabigatran, he presented 
with extensive DVT extending from the right external 
iliac to the popliteal vein. He was initially treated with 
low molecular weight heparin for recurrent thrombosis 
and bridged to warfarin therapy. He had no other risk 
factors for VTE such as malignancy or family history 
of VTE. His echocardiogram showed mild aortic root 
and ascending aorta dilatation and concentric LVH with 
diastolic dysfunction but normal right ventricular size 
and normal biventricular systolic functions. Colonoscopy 
revealed three hyperplasic polyps but was otherwise 
unremarkable. Thrombophilia testing showed: Fibrinogen 
of 3.83 g/L, antithrombin III 0.86 U/ml, anticardiolipin 
1.6 U/mL, protein C 1.6 U/mL and protein S 1.98 U/mL, 
negative prothrombin gene mutation but heterozygous 
for FVL mutation.
Discussion
VTE can be associated with significant adverse outcomes 
if not promptly recognised, whereas timely initiation 
of anticoagulation therapy significantly reduces early 
morbidity and mortality.[6] Several studies have shown 
that patients with acromegaly have abnormalities in the 
coagulation and fibrinolytic systems that could potentially 
predispose to increased risk of VTE.[3-5,7,8] Plasma 
fibrinogen, an important clotting protein produced in 
the liver, has been reported to be significantly elevated 
in individuals with active acromegaly compared with 
healthy controls and plasma fibrinogen levels have a 
positive correlation with serum IGF-1.[3] Remission of 
acromegaly with surgery or medical therapy is associated 
with a reduction in plasma fibrinogen levels.[3] Another 
study[4] assessed coagulation markers in 22 patients 
with active acromegaly and reported elevated levels of 
fibrinogen, tissue plasminogen activator (t-PA) and PA 
inhibitor-1 (PAI-1) while protein S activity and tissue 
factor plasminogen inhibitor were decreased in these 
patients compared with healthy controls, potentially 
creating a pro-thrombotic environment. Elevated PAI-I 
is both an independent risk factor for VTE and the major 
determinant of elevated plasma clot lysis time, increasing 
VTE risk even after adjusting for other coagulation and 
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fibrinolytic markers.[7] However, with the exception of 
fibrinogen and protein S, the association between most 
other coagulation and fibrinolysis markers described 
above and VTE is inconsistent and, consequently, they 
are not measured in routine thrombophilia screening.[8] 
In our patients, the thrombophilia screen was positive 
for homozygous and heterozygous FVL mutation in 
cases 2 and 3. This mutation is known to be associated 
with an increased risk of VTE in both heterozygous 
and homozygous individuals.[9] We were unable to 
find any association between acromegaly and FVL 
in a comprehensive MEDLINE search of the English 
language literature, using the keywords: “Acromegaly,” 
“thrombosis,” “coagulation” and “FVL.” The two episodes 
of DVT post-surgery in case 3 represent an additional risk 
factor for VTE whilst the slightly low protein S level in 
case 1 and weakly positive lupus anticoagulant ratio in 
case 2 are not diagnostic of thrombophilia and are likely 
clinically unimportant.
Malignancy is one of the major risk factors for VTE, 
but the associated risk is dependent on the type and 
staging of the tumour as well as therapeutic modalities.[10] 
Occasionally, VTE can be the preceding manifestation 
of an occult malignancy.[11] Several recent studies have 
shown that patients with acromegaly are at increased 
risk of developing colon, thyroid and urogenital 
malignancies.[12-14] Consequently, in patients with 
acromegaly, colonoscopy is recommended for screening 
of colon cancer.[15,16] Furthermore, acromegaly might be a 
component of other disorders such as multiple endocrine 
neoplasia type 1, McCune-Albright syndrome or other 
genetic syndromes in which additional tumours in other 
organs may coexist and therefore potentially increase the 
risk of VTE.[17] Patients with pituitary tumours who have 
received conventional radiation therapy also have a higher 
risk of developing secondary brain tumours.[18] Although 
the presence of occult malignancy is exceedingly 
difficult to exclude, we were unable to find any evidence 
of malignancy despite thorough clinical examination, 
diagnostic colonoscopy and extensive imaging studies 
including ultrasound and CT scan of the chest, abdomen 
and pelvis.
Congestive heart failure (CHF), found in some patients 
with long-standing uncontrolled acromegaly, has also 
been reported to increase the risk of VTE.[19] Blood stasis, 
chronic inflammatory-mediated endothelial dysfunction 
and reduced mobility are speculated to be among the 
potential underlying mechanisms.[19,20] In one retrospective 
case–control study, the risk of VTE was significantly 
elevated in CHF patients with ejection fraction (EF) of 
<20% compared with those having EF >45%.[19] The 
slight increase in VTE risk in the setting of preserved EF 
is thought to be due to the potential presence of diastolic 
dysfunction or right ventricular failure.[19] Echocardiogram 
results in all of our cases showed normal EF with no 
findings of right-sided heart failure or any other significant 
abnormalities to account for VTE [Table 2].
Two of our patients had previous radiation treatment and 
developed recurrence of VTE shortly after the addition of 
pegvisomant. It is unclear if localised sellar irradiation is 
associated with an increased risk of VTE. Medical therapy 
Table 2: VTE and risk factors
Risk Factors Case 1 Case 2 Case 3 
Number of VT episodes 1 5 4 
Time since first unprovoked 
episode 
21 months 71 months 23 months 
VTE risk factors No Homozygous FVL Heterozygous FVL, past 
history of DVT 
Known malignancy Negative Negative Negative 
Colonoscopy 3 hyperplastic polyps Normal 3 hyperplastic polyps 
Echocardiogram Mild diastolic dysfunction 
only 
EF 57%. Normal RV func-
tion. Elevated diastolic filling 
pressure 
Severe concentric LVH 
but normal biventricular 
function 
VTE: Venous thromboembolism, EF: Ejection fraction, DVT: Deep vein thrombosis, FVL: Factor V Leiden, LVH: Left ventricular hypertrophy
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with somatostatin analogues and pegvisomant has not 
been reported to cause VTE. Previously a small study in 
5 healthy individuals who were given a 3-day treatment of 
pegvisomant showed decreased levels of VW antigen, but 
no changes in fibrinogen, factor VIII, PAI-I, t-PA or other 
coagulation markers were observed.[21] Furthermore, data 
from the ACROSTUDY, a surveillance study of almost 
1300 patients on pegvisomant for a mean of 2.3 years, did 
not report an increased risk of VTE.[22]
FVL mutation is detected in about 25% of patients with 
VTE and is considered the most common thrombophilic 
disorder.[9] The overall prevalence has been reported to 
be approximately 5% in Caucasian Americans, 3–15% 
in Europeans and it is considered rare among Asians.[23,24] 
Whether this mutation is commoner in patients with 
acromegaly is not known. It is noteworthy that all three 
patients had longstanding uncontrolled acromegaly. 
Whether uncontrolled acromegaly simply enhances the 
risk of VTE in patients with pre-existing thrombophilic 
disorders, acts as an independent risk factor or is associated 
with an increased risk of other thrombophilic disorders, 
remains unclear. Presence of FVL mutation could 
potentially confound the association between acromegaly 
and increased VTE risk. Further studies are required to 
systematically assess this finding to appropriately counsel 
patients with acromegaly.
Conclusion
To the best of our knowledge, these cases constitute 
the first reported clinical association between active 
acromegaly and venous thrombosis. Possible explanations 
may include the presence of hereditary thrombophilia, an 
effect of GH or IGF-1 on the coagulation and fibrinolytic 
system, cardiac abnormalities or yet undiagnosed 
malignancy. Further studies should be conducted to assess 
this association.
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